In addition, IGV-001 that is being evaluated in NCT04485949 (Table 3), is a first-in-class autologous immunotherapeutic product from GoldspireTM, that combines personalized whole tumor-derived cells with an insulin-like growth factor receptor 1 (IGF-1R) antisense oligonucleotide (IMV-001) in an implantable biodiffusion chambers (204). The gene discussed is IGF1R; the disease is neoplasm.